[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569187":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":29,"responsibleParty":62,"collaborators":64,"id":66,"slug":10,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":10,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":78,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":85,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Tianjin Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Group Assignment",null,"Each subject receive a single intravenous injection of 18F-S16\u002FT807, and undergo PET\u002FCT or MRI imaging within the specificed time.",[13],"Diagnostic Test: 18F-S16\u002FT807",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":10},"DIAGNOSTIC_TEST","18F-S16\u002FT807",[9],[20,25],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Ying Wang, MD","CONTACT","+8618702292537","macrossplusvoices@163.com",{"name":26,"role":22,"phone":27,"phoneExt":10,"email":28},"Shaobo Yao, PhD","+862260362190","yaoshaobo008@163.com",[30,50],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"The First Affiliated Hospital of University of Science and Technology of China","RECRUITING","Hefei","Anhui","230000","China",{"type":38,"coordinates":39},"Point",[40,41],117.28083,31.86389,{"lat":41,"lon":40},[44,48],{"name":45,"role":22,"phone":46,"phoneExt":10,"email":47},"Qiang Xie, PhD","+8613721108043","ahxq1980@163.com",{"name":45,"role":49,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"facility":51,"status":32,"city":52,"state":53,"zip":54,"country":36,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Tianjin Medical University General Hospital","Tianjin","Tianjin Municipality","300052",{"type":38,"coordinates":56},[57,58],117.17667,39.14222,{"lat":58,"lon":57},[61],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":49,"investigatorFullName":26,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Prof.",[65],{"name":51,"class":6},"100569187",false,"NCT06690983","Tau PET\u002FCT in Various Tau-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Tau PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",true,"ALL","18 Years","80 Years",{"count":76,"type":77},500,"ESTIMATED","7 Days","OBSERVATIONAL","To evaluate the potential usefulness of 18F-S16\u002FT807 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.",[82,83,84],"Tauopathies","Neurodegenerative Diseases","Neurodegeneration",[86,87,88],"PET\u002FCT","MRI","Tau","2025-02-07",{"date":91,"type":92},"2025-02-11","ACTUAL",{"date":94,"type":92},"2018-08-01",{"date":96,"type":77},"2027-12-01",{"name":5,"class":6},2]